ABSTRACT
Purpose Gene signatures have been shown to add prognostic information beyond that of routine clinico-pathological factors, however their utility in older breast cancer patients remains unclear. As such, the aim of this study was to determine if gene signatures can provide prognostic information that may aid treatment decisions for older breast cancer patients.
Experimental design Research versions of the genomic grade index (GGI), 70-gene recurrence score (RS), cell cycle score (CCS), PAM50 Risk of Recurrence score - Proliferation (ROR-P), and PAM50 signatures were applied to 39 breast cancer datasets totalling 9583 patients. After filtering based on age ≥ 70 years, the presence of Estrogen Receptor (ER) and survival information availability 871 patients remained. The prognostic capacity of signatures was tested in all (n=871), ER-positive/lymph node-positive (ER+/LN+, n=335) and ER-positive/lymph node-negative (ER+/LN-, n=374) patients using Kaplan-Meier and multivariable Cox proportional hazard modeling.
Results All gene signatures were statistically significant in Kaplan-Meier analysis of all and ER+/LN+ patients (Log-rank P < 0.001). This significance remained in multivariable analysis (Cox proportional hazards, P ≤ 0.05). In ER+/LN-patients the GGI, 70-gene, CCS, ROR-P, and PAM50 signatures were significant in Kaplan-Meier analysis (Log-rank P ≤ 0.05) but only the 70-gene, CCS, ROR-P, and PAM50 signatures remained so in multivariable analysis (Cox proportional hazards, P ≤ 0.05).
Conclusions In general, we found that gene signatures provide prognostic information in survival analyses of all, ER+/LN+ and ER+/LN-older (≥70 years) breast cancer patients, suggesting a potential role in aiding treatment decision in older patients.
Translational Relevance The utility of gene expression signatures in breast cancer patients has been most clearly demonstrated in the TAILORx, RxPONDER and MINDACT randomised clinical trials. However, few older patients (≥70 years) were included in these trials meaning that signature utility in this patient group remains unclear. As such, we performed the first comprehensive study comparing the prognostic performance of multiple clinically relevant gene expression signatures in a single older breast cancer patient cohort. We show that in general gene signatures provide independent prognostic information in All, ER+/LN+ and ER+/LN-patients who are over the age of 70 years. These results support a potential role for signatures in aiding treatment decisions in older breast cancer patients and indicate that further investigation is warranted in prospective clinical study to elucidate their treatment predictive value.
Competing Interest Statement
N.P.T. has performed consultations to Pfizer. A.M. has performed consultations to Veracyte (no financial or any other compensation) and Roche (no financial or any other compensation). T.F. consultancy to Astra Zeneca, Gilead, Affibody, Pfizer, Novartis, Veracyte, Exact Sciences and Roche; honoraria from UpToDate; research funding to institution from Pfizer, Astra Zeneca, Novartis.
Funding Statement
This work was supported by the Iris, Stig och Gerry Castenbacks Stiftelse for cancer research (N.P.T.); the King Gustaf V Jubilee Foundation (N.P.T.); the Stockholm Cancer Society (Cancerforeningen i Stockholm to L.S.L.); the Swedish Cancer Society (Cancerfonden, N.P.T. grant number: 200802; L.S.L. grant number: 222081, 220552SIA, A.M. grant number 21 0277 JCIA 01 H); the Swedish Research Council (Vetenskapsradet, grant number 2020-02466 to L.S.L); the Swedish Research Council for Health, Working life and Welfare, (FORTE, grant number 2019-00477 to L.S.L.); ALF medicine (grant number FoUI-974882 to L.S.L.) and the Gosta Milton Donation Fund (Stiftelsen Gosta Miltons donationsfond, to L.S.L).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used in this study are publicly available on MetaGxBreast package in R (https://bioconductor.org/packages/release/data/experiment/html/MetaGxBreast.html). R-code to reproduce the results of this study are publicly available at https://bitbucket.org/tobingroup/elderly
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial support: This work was supported by the Iris, Stig och Gerry Castenbäcks Stiftelse for cancer research (N.P.T.); the King Gustaf V Jubilee Foundation (N.P.T.); the Stockholm Cancer Society (Cancerföreningen i Stockholm to L.S.L.); the Swedish Cancer Society (Cancerfonden, N.P.T. grant number: 200802; L.S.L. grant number: 222081, 220552SIA, A.M. grant number 21 0277 JCIA 01 H); the Swedish Research Council (Vetenskapsrådet, grant number 2020-02466 to L.S.L); the Swedish Research Council for Health, Working life and Welfare, (FORTE, grant number 2019-00477 to L.S.L.); ALF medicine (grant number FoUI-974882 to L.S.L.) and the Gösta Milton Donation Fund (Stiftelsen Gösta Miltons donationsfond, to L.S.L).
Disclosure of conflicts of interest: N.P.T. has performed consultations to Pfizer. A.M. has performed consultations to Veracyte (no financial or any other compensation) and Roche (no financial or any other compensation). T.F. consultancy to Astra Zeneca, Gilead, Affibody, Pfizer, Novartis, Veracyte, Exact Sciences and Roche; honoraria from UpToDate; research funding to institution from Pfizer, Astra Zeneca, Novartis.
Data Availability
The data used in this study are publicly available on MetaGxBreast package in R (https://bioconductor.org/packages/release/data/experiment/html/MetaGxBreast.html). R-code to reproduce the results of this study are publicly available at https://bitbucket.org/tobingroup/elderly
https://bitbucket.org/tobingroup/elderly
https://bioconductor.org/packages/release/data/experiment/html/MetaGxBreast.html
